Apart from our previous study that paved the way for AP-2α and AP-2γ to be considered as targeted therapy candidates [24], other authors [19] have put a different family member, AP-2δ, on the list of nearly three hundred oncogenic transcription factors and regulators, which could be a useful hint for TF-based cancer treatment. The gene discussed is TF; the disease is cancer.